A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Latest Information Update: 23 Jan 2025
At a glance
- Drugs Belzutifan (Primary) ; Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms LITESPARK-003
- Sponsors Peloton Therapeutics
Most Recent Events
- 17 Jan 2025 Results from cohort-2 of this study published in the Dana Farber Cancer Institute Media Release
- 20 Dec 2024 Planned End Date changed from 31 Aug 2025 to 26 Feb 2027.
- 20 Dec 2024 Planned primary completion date changed from 31 Aug 2025 to 26 Feb 2027.